Details of the Drug

General Information of Drug (ID: DMWQ16I)

Drug Name
Primaquine
Synonyms
Kanaprim; Primachin; Primachina; Primachinum; Primaquin; Primaquina; Primaquinum; Primachina [DCIT]; SN 13272; WR 2975; Dl-Primaquine; Kanaprim (TN); Neo-Quipenyl; Primaquina [INN-Spanish]; Primaquine (INN); Primaquine Bis-Phosphoric Acid; Primaquine [INN:BAN]; Primaquinum [INN-Latin]; SN 13,272; TG1-296; TG1-297; Ethylbutylamino)-6-methoxyquinoline; S. N. 13272; N4-(6-Methoxy-8-quinolinyl)-1,4-pentanediamine; Quinoline, 8-(4-amino-1-methylbutylamino)-6-methoxy; N(4)-(6-methoxyquinolin-8-yl)pentane-1,4-diamine; N-(5-aminopentan-2-yl)-6-methoxyquinolin-8-amine; N~4~-[6-(methyloxy)quinolin-8-yl]pentane-1,4-diamine; Quinoline, 8-[(4-amino-1-methylbutyl)amino]-6-methoxy-(6CI,8CI); (+)-N4-(6-Methoxy-8-quinolinyl)-1,4-pentanediamine; (+)-Primaquine; (+/-)-Primaquine; (-)-N4-(6-Methoxy-8-quinolinyl)-1,4-pentanediamine; (-)-Primaquine; 1,4-Pentanediamine, N4-(6-methoxy-8-quinolinyl)-(9CI); 4-N-(6-methoxyquinolin-8-yl)pentane-1,4-diamine; 6-Methoxy-8-(4-amino-1-methylbutylamino)quinoline; 6-Methoxy-8-[(4-amino-1-methylbutyl)amino]quinoline; 6-Methoxy-8-[4-amino-1-methylbutylamino]quinoline; 8-((4-Amino-1-methylbutyl)amino)-6-methoxyquinoline; 8-(4-Amino-1-m; 8-(4-Amino-1-methylbutylamino)-6-methoxyquinoline; 8-[(4-Amino-1-methylbutyl)amino]-6-methoxyquinoline
Indication
Disease Entry ICD 11 Status REF
Malaria 1F40-1F45 Approved [1]
Therapeutic Class
Antimalarials
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 259.35
Logarithm of the Partition Coefficient (xlogp) 2.2
Rotatable Bond Count (rotbonds) 6
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [2]
Bioavailability
96% of drug becomes completely available to its intended biological destination(s) [3]
Clearance
The drug present in the plasma can be removed from the body at the rate of 5.8 mL/min/kg [4]
Elimination
1% of drug is excreted from urine in the unchanged form [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 3.7 - 7.4 hours [4]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 2.8918 micromolar/kg/day [5]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 4 L/kg [4]
Chemical Identifiers
Formula
C15H21N3O
IUPAC Name
4-N-(6-methoxyquinolin-8-yl)pentane-1,4-diamine
Canonical SMILES
CC(CCCN)NC1=C2C(=CC(=C1)OC)C=CC=N2
InChI
InChI=1S/C15H21N3O/c1-11(5-3-7-16)18-14-10-13(19-2)9-12-6-4-8-17-15(12)14/h4,6,8-11,18H,3,5,7,16H2,1-2H3
InChIKey
INDBQLZJXZLFIT-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
4908
ChEBI ID
CHEBI:8405
CAS Number
90-34-6
DrugBank ID
DB01087
TTD ID
D0T1LK
INTEDE ID
DR1339
ACDINA ID
D00554
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Plasmodium Deoxyribonucleic acid (Malaria DNA) TT698WO NOUNIPROTAC Not Available [6]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [7]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [8]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Antileukoproteinase (SLPI) OTUNFUU8 SLPI_HUMAN Gene/Protein Processing [9]
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Gene/Protein Processing [10]
Cytochrome P450 1A1 (CYP1A1) OTE4EFH8 CP1A1_HUMAN Gene/Protein Processing [11]
Cytochrome P450 1A2 (CYP1A2) OTLLBX48 CP1A2_HUMAN Gene/Protein Processing [11]
Cytochrome P450 1B1 (CYP1B1) OTYXFLSD CP1B1_HUMAN Gene/Protein Processing [12]
Cytochrome P450 2B6 (CYP2B6) OTOYO4S7 CP2B6_HUMAN Regulation of Drug Effects [13]
Cytochrome P450 2D6 (CYP2D6) OTZJC802 CP2D6_HUMAN Regulation of Drug Effects [13]
Cytochrome P450 2E1 (CYP2E1) OTHQ17JG CP2E1_HUMAN Regulation of Drug Effects [13]
Glucose-6-phosphate 1-dehydrogenase (G6PD) OT300SMK G6PD_HUMAN Drug Response [14]
Hemoglobin subunit gamma-2 (HBG2) OT4J48JJ HBG2_HUMAN Gene/Protein Processing [13]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Primaquine
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Primaquine and Lumefantrine. Malaria [1F40-1F45] [15]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Primaquine and Halofantrine. Malaria [1F40-1F45] [16]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Primaquine and Hydroxychloroquine. Malaria [1F40-1F45] [17]
Coadministration of a Drug Treating the Disease Different from Primaquine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Primaquine and Ivosidenib. Acute myeloid leukaemia [2A60] [18]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Primaquine and Midostaurin. Acute myeloid leukaemia [2A60] [19]
Idarubicin DMM0XGL Moderate Increased risk of prolong QT interval by the combination of Primaquine and Idarubicin. Acute myeloid leukaemia [2A60] [19]
Arn-509 DMT81LZ Moderate Increased risk of prolong QT interval by the combination of Primaquine and Arn-509. Acute myeloid leukaemia [2A60] [20]
Gilteritinib DMTI0ZO Moderate Increased risk of prolong QT interval by the combination of Primaquine and Gilteritinib. Acute myeloid leukaemia [2A60] [21]
Oliceridine DM6MDCF Moderate Increased risk of prolong QT interval by the combination of Primaquine and Oliceridine. Acute pain [MG31] [19]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Primaquine and Ivabradine. Angina pectoris [BA40] [20]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Primaquine and Bepridil. Angina pectoris [BA40] [19]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Primaquine and Dronedarone. Angina pectoris [BA40] [19]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Primaquine and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [22]
Cilostazol DMZMSCT Moderate Increased risk of prolong QT interval by the combination of Primaquine and Cilostazol. Arterial occlusive disease [BD40] [19]
Posaconazole DMUL5EW Moderate Increased risk of prolong QT interval by the combination of Primaquine and Posaconazole. Aspergillosis [1F20] [19]
Levalbuterol DM5YBO1 Moderate Increased risk of ventricular arrhythmias by the combination of Primaquine and Levalbuterol. Asthma [CA23] [23]
Pirbuterol DMI5678 Moderate Increased risk of ventricular arrhythmias by the combination of Primaquine and Pirbuterol. Asthma [CA23] [24]
Lisdexamfetamine DM6W8V5 Moderate Increased risk of prolong QT interval by the combination of Primaquine and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [20]
Desipramine DMT2FDC Moderate Increased risk of prolong QT interval by the combination of Primaquine and Desipramine. Attention deficit hyperactivity disorder [6A05] [19]
Ofloxacin DM0VQN3 Moderate Increased risk of prolong QT interval by the combination of Primaquine and Ofloxacin. Bacterial infection [1A00-1C4Z] [25]
Clarithromycin DM4M1SG Moderate Increased risk of prolong QT interval by the combination of Primaquine and Clarithromycin. Bacterial infection [1A00-1C4Z] [19]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Primaquine and Sparfloxacin. Bacterial infection [1A00-1C4Z] [25]
Gemifloxacin DMHT34O Moderate Increased risk of prolong QT interval by the combination of Primaquine and Gemifloxacin. Bacterial infection [1A00-1C4Z] [25]
Levofloxacin DMS60RB Moderate Increased risk of prolong QT interval by the combination of Primaquine and Levofloxacin. Bacterial infection [1A00-1C4Z] [25]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Primaquine and Retigabine. Behcet disease [4A62] [19]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Primaquine and Eribulin. Breast cancer [2C60-2C6Y] [19]
Lapatinib DM3BH1Y Moderate Increased risk of prolong QT interval by the combination of Primaquine and Lapatinib. Breast cancer [2C60-2C6Y] [19]
Bosutinib DMTI8YE Moderate Increased risk of prolong QT interval by the combination of Primaquine and Bosutinib. Breast cancer [2C60-2C6Y] [20]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Primaquine and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [26]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Primaquine and Olodaterol. Chronic obstructive pulmonary disease [CA22] [24]
Vilanterol DMF5EK1 Moderate Increased risk of prolong QT interval by the combination of Primaquine and Vilanterol. Chronic obstructive pulmonary disease [CA22] [23]
Indacaterol DMQJHR7 Moderate Increased risk of ventricular arrhythmias by the combination of Primaquine and Indacaterol. Chronic obstructive pulmonary disease [CA22] [24]
Arformoterol DMYM974 Moderate Increased risk of prolong QT interval by the combination of Primaquine and Arformoterol. Chronic obstructive pulmonary disease [CA22] [24]
Halothane DM80OZ5 Moderate Increased risk of prolong QT interval by the combination of Primaquine and Halothane. Corneal disease [9A76-9A78] [19]
Sevoflurane DMC9O43 Moderate Increased risk of prolong QT interval by the combination of Primaquine and Sevoflurane. Corneal disease [9A76-9A78] [19]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Primaquine and Probucol. Coronary atherosclerosis [BA80] [19]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Primaquine and Pasireotide. Cushing syndrome [5A70] [19]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Primaquine and Osilodrostat. Cushing syndrome [5A70] [20]
Sertraline DM0FB1J Moderate Increased risk of prolong QT interval by the combination of Primaquine and Sertraline. Depression [6A70-6A7Z] [19]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Primaquine and Escitalopram. Depression [6A70-6A7Z] [19]
Clomipramine DMINRKW Moderate Increased risk of prolong QT interval by the combination of Primaquine and Clomipramine. Depression [6A70-6A7Z] [19]
Doxepin DMPI98T Moderate Increased risk of prolong QT interval by the combination of Primaquine and Doxepin. Depression [6A70-6A7Z] [19]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Primaquine and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [19]
Deutetrabenazine DMUPFLI Moderate Increased risk of prolong QT interval by the combination of Primaquine and Deutetrabenazine. Dystonic disorder [8A02] [27]
Ingrezza DMVPLNC Moderate Additive CNS depression effects by the combination of Primaquine and Ingrezza. Dystonic disorder [8A02] [28]
Solifenacin DMG592Q Moderate Increased risk of prolong QT interval by the combination of Primaquine and Solifenacin. Functional bladder disorder [GC50] [19]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Primaquine and Sunitinib. Gastrointestinal stromal tumour [2B5B] [19]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Primaquine and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [29]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Primaquine and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [30]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Primaquine and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [19]
Pirfenidone DM6VZFQ Moderate Decreased metabolism of Primaquine caused by Pirfenidone mediated inhibition of CYP450 enzyme. Idiopathic interstitial pneumonitis [CB03] [20]
Tasimelteon DMLOQ1V Moderate Decreased metabolism of Primaquine caused by Tasimelteon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [31]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Primaquine and Polyethylene glycol. Irritable bowel syndrome [DD91] [20]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Primaquine and Phenolphthalein. Irritable bowel syndrome [DD91] [19]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Primaquine and Crizotinib. Lung cancer [2C25] [32]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Primaquine and Ceritinib. Lung cancer [2C25] [19]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Primaquine and Osimertinib. Lung cancer [2C25] [33]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Primaquine and Selpercatinib. Lung cancer [2C25] [20]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Primaquine and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [20]
Arsenic trioxide DM61TA4 Major Increased risk of ventricular arrhythmias by the combination of Primaquine and Arsenic trioxide. Mature B-cell lymphoma [2A85] [34]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Primaquine and Vemurafenib. Melanoma [2C30] [19]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Primaquine and LGX818. Melanoma [2C30] [35]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Primaquine and Panobinostat. Multiple myeloma [2A83] [36]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Primaquine and Siponimod. Multiple sclerosis [8A40] [15]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Primaquine and Fingolimod. Multiple sclerosis [8A40] [19]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Primaquine and Ocrelizumab. Multiple sclerosis [8A40] [37]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Primaquine and Ozanimod. Multiple sclerosis [8A40] [38]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Primaquine and Romidepsin. Mycosis fungoides [2B01] [19]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Primaquine and Nilotinib. Myeloproliferative neoplasm [2A20] [19]
Dasatinib DMJV2EK Moderate Increased risk of prolong QT interval by the combination of Primaquine and Dasatinib. Myeloproliferative neoplasm [2A20] [39]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Primaquine and Levomethadyl Acetate. Opioid use disorder [6C43] [20]
Lofexidine DM1WXA6 Moderate Increased risk of prolong QT interval by the combination of Primaquine and Lofexidine. Opioid use disorder [6C43] [19]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Primaquine and Rucaparib. Ovarian cancer [2C73] [19]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Primaquine and Triclabendazole. Parasitic worm infestation [1F90] [19]
Rasagiline DM3WKQ4 Moderate Decreased metabolism of Primaquine caused by Rasagiline mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [15]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Primaquine and Pimavanserin. Parkinsonism [8A00] [40]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Primaquine and Lefamulin. Pneumonia [CA40] [41]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Primaquine and Degarelix. Prostate cancer [2C82] [20]
ABIRATERONE DM8V75C Moderate Increased risk of prolong QT interval by the combination of Primaquine and ABIRATERONE. Prostate cancer [2C82] [20]
Relugolix DMK7IWL Moderate Increased risk of prolong QT interval by the combination of Primaquine and Relugolix. Prostate cancer [2C82] [20]
Bicalutamide DMZMSPF Moderate Increased risk of prolong QT interval by the combination of Primaquine and Bicalutamide. Prostate cancer [2C82] [20]
Levomepromazine DMIKFEL Moderate Increased risk of prolong QT interval by the combination of Primaquine and Levomepromazine. Psychotic disorder [6A20-6A25] [19]
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of Primaquine and Golimumab. Rheumatoid arthritis [FA20] [42]
Quetiapine DM1N62C Moderate Increased risk of prolong QT interval by the combination of Primaquine and Quetiapine. Schizophrenia [6A20] [19]
Aripiprazole DM3NUMH Moderate Increased risk of prolong QT interval by the combination of Primaquine and Aripiprazole. Schizophrenia [6A20] [15]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Primaquine and Iloperidone. Schizophrenia [6A20] [19]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Primaquine and Paliperidone. Schizophrenia [6A20] [19]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Primaquine and Amisulpride. Schizophrenia [6A20] [43]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Primaquine and Asenapine. Schizophrenia [6A20] [19]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Primaquine and Pimozide. Schizophrenia [6A20] [20]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Primaquine and LEE011. Solid tumour/cancer [2A00-2F9Z] [19]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Primaquine and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [19]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Primaquine and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [20]
Pitolisant DM8RFNJ Moderate Increased risk of prolong QT interval by the combination of Primaquine and Pitolisant. Somnolence [MG42] [19]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Primaquine and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [19]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Primaquine and Lenvatinib. Thyroid cancer [2D10] [19]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Primaquine and Cabozantinib. Thyroid cancer [2D10] [20]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Primaquine and Papaverine. Tonus and reflex abnormality [MB47] [44]
Trimeprazine DMEMV9D Moderate Increased risk of prolong QT interval by the combination of Primaquine and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [45]
Propafenone DMPIBJK Moderate Increased risk of prolong QT interval by the combination of Primaquine and Propafenone. Ventricular tachyarrhythmia [BC71] [19]
Flecainide DMSQDLE Moderate Increased risk of prolong QT interval by the combination of Primaquine and Flecainide. Ventricular tachyarrhythmia [BC71] [19]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Primaquine and Amiodarone. Ventricular tachyarrhythmia [BC71] [19]
Valganciclovir DMS2IUH Moderate Additive myelosuppressive effects by the combination of Primaquine and Valganciclovir. Virus infection [1A24-1D9Z] [15]
⏷ Show the Full List of 100 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Allura red AC dye E00338 33258 Colorant
FD&C blue no. 2 E00446 2723854 Colorant
Hydrazine yellow E00409 164825 Colorant
Sunset yellow FCF E00255 17730 Colorant
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Eisenoxyd E00585 56841934 Colorant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 400 E00653 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent
Water E00035 962 Solvent
⏷ Show the Full List of 15 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Primaquine 26.3 mg tablet 26.3 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 008316.
2 BDDCS applied to over 900 drugs
3 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 Primaquine-induced differential gene expression analysis in mice liver using DNA microarrays. Toxicology. 2007 Sep 24;239(1-2):96-107.
7 Primaquine metabolism by human liver microsomes: effect of other antimalarial drugs. Biochem Pharmacol. 1992 Aug 4;44(3):587-90.
8 Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur J Clin Pharmacol. 2003 Sep;59(5-6):429-42.
9 An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. Arch Toxicol. 2021 Jan;95(1):149-168. doi: 10.1007/s00204-020-02882-4. Epub 2020 Aug 20.
10 Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010 Dec; 118(2):485-500.
11 Cytochrome P450 1A1/2 induction by antiparasitic drugs: dose-dependent increase in ethoxyresorufin O-deethylase activity and mRNA caused by quinine, primaquine and albendazole in HepG2 cells. Eur J Clin Pharmacol. 2002 Nov;58(8):537-42.
12 Time-dependent transcriptional induction of CYP1A1, CYP1A2 and CYP1B1 mRNAs by H+/K+ -ATPase inhibitors and other xenobiotics. Xenobiotica. 2003 Feb;33(2):107-18.
13 Cytochrome P(450)-dependent toxic effects of primaquine on human erythrocytes. Toxicol Appl Pharmacol. 2009 Nov 15;241(1):14-22. doi: 10.1016/j.taap.2009.07.012. Epub 2009 Jul 17.
14 Understanding the mechanisms for metabolism-linked hemolytic toxicity of primaquine against glucose 6-phosphate dehydrogenase deficient human erythrocytes: evaluation of eryptotic pathway. Toxicology. 2012 Mar 29;294(1):54-60. doi: 10.1016/j.tox.2012.01.015. Epub 2012 Feb 6.
15 Cerner Multum, Inc. "Australian Product Information.".
16 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
17 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
18 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
19 Canadian Pharmacists Association.
20 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
21 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
22 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
23 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
24 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
25 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
26 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
27 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
28 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
29 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
30 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
31 Product Information. Hetlioz (tasimelteon). Vanda Pharmaceuticals Inc, Rockville, MD.
32 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
33 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
34 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
35 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
36 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
37 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
38 Product Information. Zeposia (ozanimod). Celgene Corporation, Summit, NJ.
39 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
40 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
41 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
42 Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
43 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
44 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]
45 Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8. [PMID: 12904146]